PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury
Qianping Zhang,Tiantian Sun,Fan Yu,Wei Liu,Jin Gao,Jinyu Chen,Hao Zheng,Jinming Liu,Chenjian Miao,Huanyi Guo,Wu Tian,Meihui Su,Yingjie Guo,Xi Liu,Yandong Pei,Zhuofei Wang,Shang Chen,Chenglong Mu,Sin Man Lam,Guanghou Shui,Zongjin Li,Zhongbo Yu,Yan Zhang,Guo Chen,Congcong Lu,Adam C. Midgley,Changhua Li,Xin Bian,Xudong Liao,Yong Wang,Wei Xiong,Hongying Zhu,Yanjun Li,Quan Chen
DOI: https://doi.org/10.1038/s41589-023-01528-7
IF: 14.8
2024-01-30
Nature Chemical Biology
Abstract:Synchronized ferroptosis contributes to nephron loss in acute kidney injury (AKI). However, the propagation signals and the underlying mechanisms of the synchronized ferroptosis for renal tubular injury remain unresolved. Here we report that platelet-activating factor (PAF) and PAF-like phospholipids (PAF-LPLs) mediated synchronized ferroptosis and contributed to AKI. The emergence of PAF and PAF-LPLs in ferroptosis caused the instability of biomembranes and signaled the cell death of neighboring cells. This cascade could be suppressed by PAF-acetylhydrolase (II) (PAFAH2) or by addition of antibodies against PAF. Genetic knockout or pharmacological inhibition of PAFAH2 increased PAF production, augmented synchronized ferroptosis and exacerbated ischemia/reperfusion (I/R)-induced AKI. Notably, intravenous administration of wild-type PAFAH2 protein, but not its enzymatically inactive mutants, prevented synchronized tubular cell death, nephron loss and AKI. Our findings offer an insight into the mechanisms of synchronized ferroptosis and suggest a possibility for the preventive intervention of AKI.
biochemistry & molecular biology